摘要:
The object of the present invention is to provide a novel method for effectively producing a cyclic lactic acid oligomer, and a cyclic lactic acid oligomer produced by the method. According to the present invention, there is provided a method for producing a cyclic lactic acid oligomer represented by the following formula (1): wherein m represents an integer of 1 to 30, wherein lactides are polymerized in the presence of an alkali metal compound represented by the following formula (2): R—Y—Me (2) wherein R represents an aliphatic group, aromatic group, —Si(R10)(R11)(R12), —CH(R20) CONR21R22 or —CH(R30)COOR31, wherein each of R10, R11 and R12 independently represents an aliphatic or aromatic group, R20 represents an aliphatic group, each of R21 and R22 independently represents a hydrogen atom, aliphatic group or aromatic group, R30 represents an aliphatic group, and R31 represents a hydrogen atom, aliphatic group or aromatic group; Y represents —O—, —S— or —NR40—, wherein R40 represents a hydrogen atom, aliphatic group or aromatic group; and Me represents an alkali metal; and, a cyclic lactic acid oligomer produced by the above production method.
摘要:
The present invention provides a non-human model mammal of Alzheimer's disease (AD) containing chimeric amyloid precursor protein (APP) gene capable of producing human amyloid β peptide (Aβ) or a living part thereof, characterized in that Aβ42/Aβ40 ratio at 8-weeks-old is about 7-fold or more (about 140-fold or more in homozygote) higher compared to that of a corresponding wild-type mammal. Moreover, the present invention provides the mammal or a living part thereof, further characterized in that the level of APP expression is not significantly different compared to the corresponding wild-type mammal, and a screening method for a prophylactic and/or therapeutic drug for AD, a biomarker in biological fluids and molecular imaging of amyloid deposition or other pathological changes in the brain for an early diagnosis of AD using the mammal or a living part thereof.
摘要:
The present invention provides a non-human model mammal of Alzheimer's disease (AD) containing chimeric amyloid precursor protein (APP) gene capable of producing human amyloid β peptide (Aβ) or a living part thereof, characterized in that Aβ42/Aβ40 ratio at 8-weeks-old is about 7-fold or more (about 140-fold or more in homozygote) higher compared to that of a corresponding wild-type mammal. Moreover, the present invention provides the mammal or a living part thereof, further characterized in that the level of APP expression is not significantly different compared to the corresponding wild-type mammal, and a screening method for a prophylactic and/or therapeutic drug for AD, a biomarker in biological fluids and molecular imaging of amyloid deposition or other pathological changes in the brain for an early diagnosis of AD using the mammal or a living part thereof.
摘要:
The object of the present invention is to provide a novel method for effectively producing a cyclic lactic acid oligomer, and a cyclic lactic acid oligomer produced by the method. According to the present invention, there is provided a method for producing a cyclic lactic acid oligomer represented by the following formula (1): wherein m represents an integer of 1 to 30, wherein lactides are polymerized in the presence of an alkali metal compound represented by the following formula (2): R—Y—Me (2) wherein R represents an aliphatic group, aromatic group, —Si(R10)(R11)(R12), —CH(R20)CONR21R22 or —CH(R30)COOR31, wherein each of R10, R11 and R12 independently represents an aliphatic or aromatic group, R20 represents an aliphatic group, each of R21 and R22 independently represents a hydrogen atom, aliphatic group or aromatic group, R30 represents an aliphatic group, and R31 represents a hydrogen atom, aliphatic group or aromatic group; Y represents —O—, —S— or —NR40—, wherein R40 represents a hydrogen atom, aliphatic group or aromatic group; and Me represents an alkali metal; and, a cyclic lactic acid oligomer produced by the above production method.